Leukocyte activation during cardiopulmonary bypass: Limitations of the inhibitory mechanisms and strategies

Journal of Cardiovascular Surgery

Volumn 41, Issue 6, 2000, Pages 849-862

  Kaul, T K ^a   Fields, B L ^a  

^a Baptist Medical Center   (United States)

Author keywords

Cardiopulmonary bypass; Complement; Leukocytes

Indexed keywords

ALLOPURINOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APROTININ; ARACHIDONIC ACID; CYTOKINE; DEFEROXAMINE; DEXAMETHASONE; HEPARIN; HETASTARCH; INDOMETACIN; INTEGRIN; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; NAFAMSTAT MESILATE; NITROUS OXIDE; OXYGEN; POLYGELINE; PROTEINASE INHIBITOR; SELECTIN; STEROID;

ARACHIDONIC ACID METABOLISM; ARTICLE; AUTOREGULATION; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CYTOKINE RELEASE; FIBRINOLYSIS; FILTER; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE INHIBITION; OXYGENATOR; PERFUSION; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PROGNOSIS; ULTRAFILTRATION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; HEART DISEASES; HUMANS; LEUKOCYTES; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0034485809     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Complement activation during cardiopulmonary bypass, evidence of generation of C3a and C5a anaphyllotoxins
2. Platelet and neutrophil activation in cardiopulmonary bypass
3. Prospects of understanding and eliminating deleterious effects of cardiopulmonary bypass
4. The systemic inflammatory response to cardiopulmonary bypass: Pathopysiological, therapeutic and pharmacological consideration
5. Complement and the damaging effects of cardiopulmonary bypass
6. Association of complement activation and elevated plasma C5a with adult respiratory distress syndrome: Pathophysiologic relevance and possible prognostic value
7. Biological effects of the human complement fragments C5a and C5a des arg on neutrophil function
8. The complement system of man
9. Chemistry and reaction mechanism of complement
10. Complement activation and lung permeability during cardiopulmonary bypass
11. Cardiopulmonary bypass and complement activation. Involvement of classic and alternate pathways
12. Pathways to complement activation during cardiopulmonary bypass
13. Reduced complement activation during bypass by prime manipulation
14. Human neutrophil degranulation during extra-corporeal circulation
15. Deposition of terminal C5-9 complement complexes on erythrocytes and leucocytes during cardiopulmonary bypass
16. Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11B/CD18 and L-selectin expression and release of IL-8 and elastase in simulated cardiopulmonary bypass
17. Activator of classic pathway of complement by Hageman factor fragment
18. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements and hemodynamic state
19. Ultrafiltration and modified ultrafiltration in pediatric open heart operations
20. The selectin GMP-140 binds to sialyated fucosylated lactosamino glycans on both myeloid and non myeloid cells
21. Oxygen radicals induce human endothelial cell to express GMP-140 and bind neutrophils
22. In vivo neutralization of P-selectin proteins feline heart and endothelium in myocardial ischemia and reperfusion injury
23. Oxygen free radical generation during cardiopulmonary bypass. Correlation with complement activation
24. Increased production of peroxidase production associated with cardiac operations. Evidence of free radical generation
25. Lung performance following cardiopulmonary bypass. The potential role of oxygen free radicals
26. Free radical tissue injury
27. Induction of superoxide anion production monocytes and leucocytes by activated platelets through p-Selectin-Sialyl Lewis x interaction
28. Role of oxygen derived free radicals and metabolites in leucocyte dependent inflammatory reaction
29. Evidence for role of hydroxyl radical in complement and neutrophil dependent tissue injury
30. Formation of CI s-CI inhibitor, Kallikrein-CI-inhibitor plasma-Plasmin inhibitor complexes
31. Free radicals and reperfusion induced arrhythmia protection by spin trap agent PNB in the rat heart
32. Cytokine balance and immuno suppression changes at cardiac surgery, contrasting response between patients and isolated cardiopulmonary bypass circuits
33. Nitric oxide: An endogenous modulator of leucocyte adhesion
34. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocyte: An autoregulatory role of IL-10 produced by monocyte
35. Direct measurement of free radical generation following reperfusion of ischemic myocardium
36. Neutrophils and ARDS
37. ARDS changing concepts
38. The mechanism and management of non cardiogenic pulmonary oedema following cardiopulmonary bypass
39. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenator
40. The effect of methylprednisolone on complement mediated neutrophil activation during cardiopulmonary bypass
41. Effects of methylprednisolone on complement activation and leucocyte counts during cardiopulmonary bypass
42. Corticosteroids increase blood IL-10 levels during cardiopulmonary bypass in men
43. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in human
44. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass
45. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass
46. Complement and the damaging effects of cardiopulmonary bypass
47. Regulation of acute phase response after cardiopulmonary bypass by immunomodulation
48. Allopurinol, deferoxamine, DMTU prevent reperfusion lung injury
49. Deferoxamine reduces neutrophil mediated free radical production during cardiopulmonary bypass in man
50. Inhibition of iron catalysed formation of hydroxyl radical from superoxide and lipid peroxidation by deferoxamine
51. Low dose aprotinin modifies hemostasis but not proinflammatory cytokine release
52. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass induced inflammation in human
53. Aprotinin reduces IL-8 production and lung neutrophil accumulation after cardiopulmonary bypass
54. Attenuation of cardiopulmonary bypass derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations
55. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175
56. Soluble human complement receptor type one; in vivo inhibitor of complement suppressing postischemic myocardial inflammation necrosis
57. Adult respiratory distress syndrome following cardiopulmonary bypass incidence, prophylaxis and management
58. Inhibition of complement in human lung transplant reperfusion injury; A multicentric clinical trial
59. Heparin coated circuit reduces the inflammatory response to cardiopulmonary bypass
60. Reduced complement activation with heparin coated oxygenator and tubing in coronary bypass operation
61. Reduced complement and granulocyte activation with heparin coated cardiopulmonary bypass
62. Influence of Duraflo II heparin treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass
63. Attenuation of changes in leucocyte surface markers and complement activation with heparin coated cardiopulmonary bypass
64. Complement activation during cardiopulmonary bypass: Effects of immobilised heparin
65. Heparin coated extracorporeal circuit reduces formation of Kallikrein CI-inhibitor complex as compared with uncoated circuit
66. Complement activation in cardiopulmonary bypass with special reference to anaphyllotoxin production in membrane and bubble oxygenators
67. Membrane oxygenator prevents lung perfusion injury in canine cardiopulmonary bypass
68. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting
69. Complement inhibition with soluble complement receptor type I in cardiopulmonary bypass
70. Influence of 4 different membrane oxygenators on inflammation like process during extracorporeal circulation with pulsatile and non pulsatile flow
71. Heparin coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model
72. Biocompatibility of heparin coated membrane oxygenator during cardiopulmonary bypass
73. Pulsatile compared with non pulsatile perfusion using a centifugal pump for cardiopulmonary bypass: Effects on systemic hemodynamics, oxygenation and inflammatory response parameters
74. Leucocyte and platelet depletion with a blood cell separator. Effects on lung injury after cardiac surgery with cardiopulmonary bypass
75. Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiopulmonary status
76. Neutrophil mediated lung injury after extracorporeal perfusion
77. The influence of leucocyte filtration during cardiopulmonary bypass on postoperative lung function. A clinical study
78. Pall leucocyte depleting filter during cardiopulmonary bypass
79. Indications for ultrafiltration in cardiac surgical practice
80. Continuous arterio-venous hemofiltration after cardiac operations in infants and children
81. Hemofiltration modifies complement activation after extra corporeal circulation in infants
82. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery, effects on hemostasis, cytokines and complement components
83. Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operation
84. Post bypass versus continuous modified ultrafiltration during CABG
85. Experimental studies of the influence of priming solutions on the systemic activation of complement during cardiopulmonary bypass. Comparison between the use of abbumen, hydroxyl starch and HW-137
86. Effects of pentastarch-deferoxamine conjugate on lung injury after cardiopulmonary bypass
87. A potential mechanism of vasodilatation after warm heart surgery: The temperature dependent release of cytokines
88. Hypothermic versus normothermic cardiopulmonary bypass
89. Normothermia versus hypothermia during cardiopulmonary bypass: A randomized controlled trial
90. Evidence of complement activation by protamine-heparin interaction after cardiopulmonary bypass
91. Neutrophil adhesion blockade with NPC 15669 decreases pulmonary injury after total cardiopulmonary bypass
92. Pentoxyphylline reduces lung allograft reperfusion injury
93. Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts
94. Effect of cardiac surgery in cardiopulmonary bypass on lidocaine deposition
95. Nitroprusside reduces lung allograft reperfusion injury
96. Carbohydrate selectin inhibitor CY-1503 reduces neutrophil migration and reperfusion injury in canine pulmonary allografts
97. Therapeutic potential of inhibiting leucocyte rolling in ischemia reperfusion injury
98. A novel sialyl Lewis x analouge attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion
99. Attenuation of rat lung isograft reperfusion injury with anti adhesion molecule monoclonal antibodies
100. Lung reperfusion injury is reduced by inhibiting CD18 dependent mechanism
101. Increased pulmonary alveolar-capillary permeability in patients with risk of AHDS
102. Low molecular weight heparin